Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Triheptanoin by Ultragenyx Pharmaceutical for Medium-Chain Acyl-CoA Dehydrogenase Deficiency: Likelihood of Approval
Triheptanoin is under clinical development by Ultragenyx Pharmaceutical and currently in Phase II for Medium-Chain Acyl-CoA Dehydrogenase Deficiency. According to...
Data Insights
Triheptanoin by Ultragenyx Pharmaceutical for Neurodegenerative Diseases: Likelihood of Approval
Triheptanoin is under clinical development by Ultragenyx Pharmaceutical and currently in Phase I for Neurodegenerative Diseases. According to GlobalData, Phase...